A Systematic Review and Meta-Analysis on the Efficacy of Repeated Transcranial Direct Current Stimulation for Migraine.

PURPOSE: Transcranial direct current stimulation (tDCS) may have therapeutic potential in the management of migraine. However, studies to date have yielded conflicting results. We reviewed studies using repeated tDCS for longer than 4 weeks in migraine treatment, and performed meta-analysis on the efficacy of tDCS in migraine.
METHODS: In this meta-analysis, we included the common outcome measurements reported across randomized controlled trials (RCTs). Subgroup analysis was performed at different post-treatment endpoints, and with different stimulation intensities and polarities.
RESULTS: Five RCTs were included in the quantitative meta-analysis with a total of 104 migraine patients. We found a significant reduction of migraine pain intensity (MD: -1.44; CI: [-2.13, -0.76]) in active vs sham tDCS treated patients. Within active treatment groups, pain intensity and duration were significantly improved from baseline after tDCS treatment (intensity MD: -1.86; CI: [-3.30, -0.43]; duration MD: -4.42; CI: [-8.11, -0.74]) and during a follow-up period (intensity MD: -1.52; CI: [-1.84, -1.20]; duration MD: -1.94; CI: [-3.10, -0.77]). There was a significant reduction of pain intensity by both anodal (MD: -1.74; CI: [-2.80, -0.68]) and cathodal (MD: -1.49; CI: [-1.89, -1.09]) stimulation conditions.
CONCLUSION: tDCS treatment repeated over days for a period of 4 weeks or more is effective in reducing migraine pain intensity and duration of migraine episode. The benefit of tDCS can persist for at least 4 weeks after the completion of last tDCS session. Both anodal and cathodal stimulation are effective for reducing migraine pain intensity.

Introduction

Migraine is one of the most common neurological disorders associated with significant disability.1,2 The global prevalence of migraine was estimated at 14.7% (around 1 in 7 people).3 Defined as a primary headache disorder with repeated episodic flare up lasting 4–72 hours, characteristic migraine headache has moderate to severe head pain intensity, unilateral location and throbbing/pulsating pain quality, associated with photophobia, nausea and/or vomiting.4

The exact pathophysiology of migraine is still unknown and is thought to involve both central and peripheral nervous systems.5 Current advances in migraine research suggest that calcitonin gene-related peptide (CGRP) plays a significant role in the activation of trigeminal vascular pathway that is sufficient to trigger a cascade of downstream effect of neurogenic inflammation, mast cell degranulation and vasodilatation.6 Even though CGRP receptor antagonists have emerged as a promising therapeutic opportunity for the management of migraine7 along with other pharmaceutical treatments such as ergots, triptans, 5-HT 1F receptor agonist, these are generally of moderate efficacy but may have low tolerability due to adverse effects such as gastrointestinal disturbances, memory and concentration problems, fatigue, and nausea.8 Therefore, there is an unmet clinical need for using novel non-pharmacological interventions for this debilitating primary headache disorder.

Non-invasive brain stimulation (NIBS) has emerged as a promising therapeutic option for migraine management due to its potential ability to induce changes in brain plasticity.9 NIBS includes but is not limited to transcranial magnetic stimulation (TMS), transcranial electrical stimulation such as transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS), transcutaneous auricular vagus nerve stimulation, peripheral nerve stimulation (vagus nerve, trigeminal nerve, supraorbital nerve, occipital nerve), pulsed radio frequency, transcranial near-infrared stimulation (NIRS) and electro acupuncture. So far, only single pulse TMS, vagus nerve stimulation (VNS), and supraorbital neurostimulation have been approved by FDA for migraine.

Widely investigated across a range of therapeutic applications, tDCS has advantages of low cost, device portability for potential home use, well-established safety and tolerability. Depending on the montage configurations, the electrical field generated via tDCS generally spreads to nearby cortical and subcortical structures.10 Duration of electrical changes is typically maintained only for an hour locally after one time tDCS treatment,11 while sustained and repeated tDCS sessions can provoke cumulative and long-lasting neuroplastic changes in the cerebral cortex.12 Even though the majority of current clinical trials using tDCS for a variety of neurological disorders have been limited by the number of sessions (many studies report findings after 10 or less daily sessions), those that have used extended designs have demonstrated cumulative behavioral13,14 and motor15 effects.

A systematic review and meta-analysis in 201616 suggested that tDCS could be a promising non-pharmaceutical alternative for migraine. Another meta-analysis in 201917 evaluated the effect of both TMS and tDCS for migraine treatment, and found that the excitatory stimulation of primary motor cortex (M1) may reduce the intensity and frequency of headache in migraine patients.17 However, these studies did not focus on repetitive tDCS treatment of at least 4 weeks. Recently published studies used different tDCS sessions for migraine yield inconsistent results, which may be partially associated with insufficient treatment as repetitive tDCS stimulation may enhance brain plasticity via long-term potentiation (excitatory) or long-term depression (inhibitory).18

There is a paucity of comprehensive analysis on repetitive tDCS treatment results and whether tDCS has long-term effects on migraine. Furthermore, subgroup analysis to compare specific stimulation polarity (anodal and cathodal) is needed. The aim of this review was to summarize and critically evaluate human studies examining the efficacy of repetitive tDCS for at least 4 weeks for management of migraine. Additionally, we provided suggestions to facilitate tDCS clinical trials for migraine in the future.

Methods

Literature Search

Literature search was conducted in three databases including PubMed, EMBASE and Web of Science from the date of first available article up to December 2019. We identified studies related to tDCS and migraine using keywords “tDCS” or “Transcranial Direct Current Stimulation” for tDCS and “Migraine”, “Migraine Disorders”, “Migraine Headache”, “Migraine with Aura”, “Migraine without Aura” or “Chronic Migraine” for migraine. No other filters were used. We applied the principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement19 to further screen and filter studies.

Two reviewers independently screened studies to determine whether they meet the eligibility criteria shown below. To solve the differences, reviewers negotiated together or consulted with the third reviewer. Then, the full text of all potentially relevant studies was analyzed to verify compliance with eligibility criteria and whether the results were adequately reported.

Eligibility Criteria

We followed the PICOS20 (Participants, Intervention, Comparators/Controls, Outcomes, Study types) framework to organize the inclusion criteria. Participants (P): adults 18‐65 years old with migraine including migraine with/without aura and chronic migraine; Interventions (I): transcranial direct current stimulation (tDCS); Comparators/Controls (C): sham stimulation treatment; Outcomes (O): outcomes related to headache intensity, duration of each headache episode, migraine frequency, number of headache attacks and use of pain medication; and Study types (S): randomized controlled trials (RCTs).

We excluded studies that did not used randomized controlled designs as well as those that: (1) administered fewer than 145 repetitive tDCS stimulation sessions (i.e., less than 4 weeks of treatment); (2) used other types of electrical stimulation instead of sham for control comparison; (2) included subjects with headache disorders other than migraine; (3) were published in the form of reviews, conference abstract/posters, editorials, or consensus guidelines; and/or (4) provided insufficient data for analyses (such as raw data, means or p-values only).

Risk of Bias Assessment

Two researchers independently assess risk of bias of each study. Discrepancies were resolved by a third researcher. The following criteria were considered to assess the risk of bias in our analysis: sequence generation (selection bias), allocation sequence concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias), and other potential sources of bias.21 The RevMan 5.3 software was applied to assess and visualize such Cochrane risk of bias.

Data Extraction and Data Items

Data were extracted by the same researcher from each article and included the following items: study design (type, randomization, and blinding), participants in each group, stimulation protocols (montage-stimulation electrode and reference electrode, electrode size, current intensity and duration), outcome measurements, and results. Outcomes included head pain intensity (scaled from 0 to 10 monthly) and duration of each migraine episode (hours per migraine per month). We also reviewed studies on migraine frequency (migraine-related days per month), number of migraine attacks (monthly average), and use of pain medications (monthly average). However, only very few studies reported these outcomes and therefore we did not perform meta-analysis.

Data Analysis

For the meta-analysis, we processed data at three phases (before stimulation, after the last stimulation and in the follow-up phase). Two outcome measurements were investigated: pain intensity and duration of each migraine episode. Based on the central limit theorem, we assumed the difference of means of samples in comparison is normally distributed, thus we can calculate mean difference (MD) and 95% confidence interval (CI) from the standard normal distribution with mean and standard deviation or p–value estimated in each study. Upon availability, either mean or median difference were considered as good estimator of population mean difference. Studies used two different scale ranges for pain intensity, either with a 0–3 or 0–10 score range. Therefore, for uniform comparison, we normalized the pain intensity measurement to a 0–10 score scale for all studies by min-max normalization.

To evaluate the efficacy of tDCS treatment, we performed between-group and within-group analyses. For between-group analysis (active versus sham), we compared the change of each outcome measurement in tDCS treatment group with that in sham group. The mean change was calculated by comparing the mean measurement after treatment with that before treatment. For within-group analysis, we compared the changes in outcome measures after the intervention within the tDCS treatment group and the sham group (if available) separately. In each group, the mean effect showing after treatment was assessed by the change of measurement after last stimulation from baseline, and the long-term effect was assessed by the change of measurement at the follow-up endpoint from baseline. Using the same analysis approach, we further conducted a subgroup comparison to evaluate the effects of stimulation polarity (anodal versus cathodal). To account for the heterogeneity, all pooled effects were estimated from meta-analysis using random-effects models.

We used R (v.3.6.3) software for data processing and obtained summary statistics including the mean and the 95% confidence interval of difference. With the summary statistics, meta-analysis was performed using the Comprehensive Meta-Analysis (CMA) V3 software (Biostat, NJ, USA). We also evaluated the impact of each study on the overall effect size by sensitivity analysis using the one-study remove (leave-one-out) approach.22

Results

Selection and Characteristics of Studies, and Bias Risks Assessment

According to the search criteria, our preliminary search yielded 267 results in which 155 non-duplicated studies were identified. Removing irrelevant and incomplete articles such as meeting abstracts and posters, 84 articles were left for rigorous screening of eligibility. Finally, a total of 5 eligible studies were included for meta-analysis. The detailed procedure for the study selection and exclusion is shown in Figure 1. Data from a total of 104 migraine patients receiving either active or sham tDCS were used to evaluate of the effects of tDCS on migraine pain intensity and duration of each migraine episode. We provided the summary of these studies in Table 1.

Figure 1

PRISMA flow diagram for study selection.

Notes: Adapted from Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097.19

Table 1

Characteristics of Studies Included in Meta-Analysis

First Author Year	Study Design	Diagnostic Criteria	Participants	Age Mean (SD)	Sex	Baseline Duration	Treatment Duration	Follow-Up Duration	Outcomes
Andrade 201727	Double-blind randomized sham-controlled	ICHD-III beta	n=13 (T:9, S:4)	T:31.77(14.0), S:34.5(13.4)	T:5F/4M, S:2F/2M	Unspecified	4 weeks	Unspecified	Pain intensity
Rocha 201526	Double-blind randomized, sham-controlled	ICHD-II	n=15 (T:10, S:5)	T:22(4), S:28(14)	T:9F/1M, S:5F	4 weeks	4 weeks	4 weeks	Pain intensity, duration of migraine episode, number of migraine attacks, use of pain medications
Auvichayapat 201223	Double-blind, randomized, sham-controlled	ICHD-II	n=37 (T:20, S:17)	T:28.60(6.83), S:35.06(13.54)	T:14F/6M, S:12F/5M	4 weeks	4 weeks	4,8,12 weeks	Pain intensity, number of migraine attacks, use of pain medications
Dasilva 201225	Single-blind, randomized, sham-controlled	ICHD-II	n=13 (T:8, S:5)	T:45.2(6.9), S:45(4.2)	T:5F/3M, S:3F/2M	1 week	4 weeks	8,16 weeks	Pain intensity, duration of migraine episode
Antal 201124	Single-blind, randomized, sham-controlled	ICHD-II	n=26 (T:13, S:13)	T:33.2(10.4), S:32.3(12.3)	T:12F/1M, S:11F/2M	8 weeks	6 weeks	8 weeks	Pain intensity, migraine frequency, duration of migraine episode, number of migraine attacks

Abbreviations: T, treatment group; S, sham group; F, female; M, male.

We evaluated possible risks of bias for each individual study according to the Cochrane handbook22 and summarized in Figure 2. Three studies23–25 shown potential risks of selection bias, including two studies did not specify or mention the methods used for randomization and hidden allocation23,25 and one study performed random sequence generation by using the patient order of entrance in the study.24 Except for Rocha’s study,26 which had a high rate of loss to follow–up, all studies were considered to have a lower risk of attrition bias.

Figure 2

Risk of bias summary. Green “+“, red “-” and yellow “?“ were used to classify the risk of bias of each criteria as: “low risk of bias“, ”high risk of bias“ and “unclear“.

tDCS Protocols

tDCS delivers mild electric current passed through two electrodes placed on the scalp to target the regions of interest, with positioning based on the international 10–20 EEG electrode placement system. The electrode montage varied in position across studies, including the L-M1 (C3),23,25,27 L–DLPFC (F3),27 and primary visual cortex (Oz).24,26 The reference electrode was placed away from the stimulation electrode, located at the contralateral superior orbital area (Fp2),23,25,27 or vertex (Cz).24,26 Three studies used anodal stimulation23,25,27 and two studies used cathodal stimulation.24,26 One study used electrodes size of 5*5 cm27 and the others used that of 5*7 cm.23–26 In all studies, the stimulation intensity of tDCS was between 1~2 mA.

tDCS effects are cumulative, with protocols administering daily or near-daily treatments of 15 to 20 minutes in duration. Baseline duration among studies ranged from 1 week to 8 weeks, treatment length varied from 4 weeks to 6 weeks, and follow-up duration ranged from 4 to 16 weeks. In addition, one study conducted electrophysiological studies before tDCS treatment,26 showing that tDCS can restore the abnormal visual cortical excitability in migraine patients. We summarized the included studies in Tables 1 and 2.

Table 2

Characteristics of the tDCS Stimulation Protocol of the Included Studies

First Author Year	Participants	tDCS Device	Stimulation	Stimulation Electrode	Reference Electrode	Electrode Size	Current Intensity	Durationof each tDCS Stimulation
Andrade 201727	n=13(T:9, S:4)	A neurostimulator by TransCranial Technologies (Hong Kong, China)	Anodal	Left M1 or left DLPFC	Right SO	5×5 cm	2 mA	20 min
Rocha 201526	n=15(T:10, S:5)	A battery-driven constant current stimulator by NeuroConn (Germany)	Cathodal	Cathodal, Oz	Cz	5×7 cm	2 mA	20 min
Auvichayapat 201223	n=37(T:20, S:17)	Constant current stimulator by Pattawit Electronic, JP advance LTD (Thailand)	Anodal	Left M1	Right SO	5×7 cm	1 mA	20 min
Dasilva 201225	n=13(T:8, S:5)	A tDCS product by Magstim (UK)	Anodal	Left M1	Right SO	5×7 cm	2 mA	20 min
Antal 201124	n=26(T:13, S:13)	A specially developed, battery-driven constant current stimulator by NeuroConn (Ilmenau, Germany)	Cathodal	Cathodal, Oz	Cz	5×7 cm	1 mA	15 min

Abbreviations: T, treatment group; S, sham group.

Pain Intensity

The active vs sham tDCS participants had significantly higher reduction of pain intensity. Based on a 10-point scale, the reduction of pain intensity in active group was 1.44 points more than that in sham group (MD: −1.44, 95% CI: [−2.13, −0.76]; P<0.01; Figure 3A).

Figure 3

Pain intensity Meta-analysis in treatment group. (A) Between group analysis; (B) after versus baseline and follow-up versus baseline; (C) subgroup analysis considering type of stimulation; (D) subgroup analysis considering current intensity.

Within the active tDCS participants, the pain intensity after treatment with tDCS stimulation was significantly lower than the baseline (after tDCS treatment (MD: −1.86, 95% CI: [−3.30, −0.43]; P=0.01; Figure 3B). Significant reduction of pain intensity was also found in the long-term follow-up period (MD: −1.52, 95% CI: [−1.84, −1.20]; P<0.01). Further, we observed significant effects of both anodal (MD: −1.74, 95% CI: [−2.80, −0.68]; P<0.01) and cathodal (MD: −1.49, 95% CI: [−1.89, −1.09]; P<0.01) stimulation on pain intensity (Figure 3C). In addition, the significant reduction was achieved by both 1mA (MD: −1.50, 95% CI: [−1.83, −1.17]; P<0.01) and 2mA (MD: −1.86, 95% CI: [−3.30, −0.43]; P=0.01; Figure 3D) current intensities (Figure 3D). Within the sham participants, we did not observe a significant difference after treatment compared to the baseline () or between different types of stimulation ( and ).

Duration of Each Migraine Episode

There was a trend in reduction of migraine duration (1.31 hrs) in the active vs sham tDCS participants. However, the reduction was not statistically significant (MD: −1.31, 95% CI: [−3.03, 0.41]; P=0.14; Figure 4A).

Figure 4

Duration of migraine episode Meta-analysis in treatment group. (A) Between group analysis; (B) after versus baseline and follow-up versus baseline; (C) subgroup analysis considering type of stimulation; (D) subgroup analysis considering current intensity.

Within the active tDCS participants, a significant reduction was observed in migraine headache duration after treatment (MD: −4.42, 95% CI: [−8.11, −0.74]; P=0.02) and in follow-up period (MD: −1.94, 95% CI: [−3.10, −0.77]; P<0.01) as compared to the baseline (Figure 4B). Although not significant, we found a trend of reduction after applying cathodal stimulation (MD: −2.61, 95% CI: [−5.29, 0.08]; P=0.06). In the only study which applied anodal stimulation, there was no reduction in migraine duration (MD: −3.00; 95% CI: [−11.04, 5.04]; P=0.46) (Figure 4C). Both treatments with 1mA (MD: −1.75, 95% CI: [−2.98, −0.52]; P=0.01) and 2mA (MD: −4.42, 95% CI: [−8.11, −0.74]; P=0.02) current intensities significantly reduced the migraine duration (Figure 4D). Within the sham participants, there was no significant effect on the duration of headache episode after treatment or in the follow-up period () using cathodal stimulation () or anodal stimulation at different current intensities ().

Other Outcomes

Additionally, we performed a narrative review on tDCS efficacy in terms of migraine days per month, number of migraine attacks per month, and the use of pain medications. Not all studies reported these outcome measures and therefore we did not perform meta-analysis. We summarized the reported results of these studies in Table 3. Using the data from the original studies, we tested the differences of each outcome measurement in active vs sham tDCS treatment participants by accounting the difference in the baseline assessment (see Methods).

Table 3

tDCs on Migraine Days per Month, Number of Migraine Attacks and the Use of Pain Medications

Study	Comparison	Mean±SD	Mean±SD	p-value
Migraine Days Per Month
Antal, 201124	Follow-up versus baseline in active group	Baseline 8.10±1.20	Follow-up 4.66±0.75	0.004
	Follow-up versus baseline in sham group	Baseline 6.40±1.39	Follow-up 5.50±1.75	0.17
	Original study, active tDCS versus sham	Follow-up 4.66±0.75	Follow-up 5.50±1.75	0.61
	Our analysis, active tDCS versus sham	−3.45±1.42	−0.90±2.23	0.001
Number of Migraine Attacks
Rocha, 201526	After last stimulation versus baseline in active group	Baseline 7.30±4.70	After last stimulation 6.30±5.00	0.242
	Follow-up versus baseline in active group	Baseline 7.30±4.70	Follow-up 3.90±2.90	0.027
	After last stimulation versus baseline in sham group	Baseline 14.70±13.60	After laststimulation 11.30±7.60	Not available
	Follow-up versus baseline in sham group	Baseline 14.70±13.60	Follow-up 9.00±10.40	Not available
	Original study, active tDCS versus sham	Not available	Not available	Not available
	Our analysis, active versus sham	−1.00±6.86	−3.40±15.58	0.672
	Our analysis, active versus sham follow-up	−3.40±5.52	−5.70±17.12	0.691
Auvichayapat, 201223	Follow-up versus baseline in active group	Baseline 3.85±0.88	Follow-up 2.80±0.69	<0.01
	Follow-up versus baseline in sham group	Baseline 3.76±0.90	Follow-up 3.71±0.92	0.33
	Original study, active tDCS versus sham	Not available	Not available	Not available
	Our analysis, active versus sham	−1.05±1.12	−0.05±1.29	0.012
Antal, 201124	Follow-up versus baseline in active group	Not available	Not available	0.38
	Follow-up versus baseline in sham group	Not available	Not available	0.2
	Original study, active tDCS versus sham	Not available	Not available	0.88
	Our analysis, active versus sham	Not available	Not available	Not available
Use of Pain Medications
Rocha, 201526	After last stimulation versus baseline in active group	Baseline 3.70±2.20	After laststimulation 1.70±1.90	0.026
	Follow-up versus baseline in active group	Baseline 3.70±2.20	Follow-up 1.60±1.10	0.05
	After last stimulation versus baseline in sham group	Baseline 12.7±15.1	After laststimulation 8.70±10.00	Not available
	Follow-up versus baseline in sham group	Baseline 12.7±15.1	Follow-up 8.70±10.70	Not available
	Original study, active tDCS versus sham	Not available	Not available	Not available
	Our analysis, active versus sham	−2.00±2.91	−4.00±18.11	0.724
	Our analysis, active versus sham follow-up	−2.10±2.46	−4.00±18.51	0.74
Auvichayapat, 201223	Follow-up versus baseline in active group	Baseline 19.40±2.62	Follow-up 14.00±3.60	<0.01
	Follow-up versus baseline in sham group	Baseline 20.65±3.59	Follow-up 16.80±3.90	<0.01
	Original study, active tDCS versus sham	Not available	Not available	Not available
	Our analysis, active versus sham	−5.40±4.45	−3.85±5.30	0.333

Note: p-values less than 0.05 were shown in bold.

Migraine Days per Month

Only one study24 meet our eligibility criteria in evaluating migraine frequency. This study found a significant reduction in migraine-related days after stimulation in the active tDCS group (p=0.004) but not in the sham group (p=0.17). While the original study did not find a significant difference between active and sham participants (p=0.61), the investigators had not accounted for the migraine frequency difference between the groups in the baseline. Our re-analysis found that headache frequency improved in the active vs sham tDCS participants by 3.45 days (p=0.001).

Number of Migraine Attacks per Month

Although three studies23,24,26 investigated the efficacy of tDCS on monthly migraine attacks, Antal et al did not report raw values (only the p values). When comparing to the sham group, the data from Auvichayapat et al23 showed a significant reduction of the number of migraine attacks in the active tDCs group (p=0.012). We did not observe a significant reduction in Rocha et al26 study.

Within the active tDCS group, two studies23,26 found that attack frequency was significant decreased in the follow-up period when compared to baseline, while the study of Antal et al found no significant difference.24 No statistically significant reduction was found within the sham group.

Use of Pain Medications

We reviewed two studies23,26 and found no difference on the use of pain medications when comparing to active tDCS to sham group. However, active tDCS was associated with a statistically significant reduction in use ofabortive medications, including ergotamine, ibuprofen, acetaminophen, triptans, paracetamol, and others as compared to baseline. Notably, Auvichayapat et al23 showed a statistically significant reduction in the use of abortive medications in a follow–up period (p<0.01). Our further review found a significantly higher intake of pain medication at baseline in sham group (12.7±15.1 tablets) compared to the tDCS treatment group (3.7±2.2 tablets) in that study.26 After adjusting the difference in the baseline, we did not find a significant reduction in pain medications use in the active tDCS versus sham participants.

Discussion

There is a growing body of literature addressing the use of tDCS for the management of migraine but very few studies have evaluated repeated tDCS stimulation treatments spanning 4 weeks or longer. Combining across variations in tDCS parameters including polarity, montage, and stimulation intensity between 1–2 mA, we found that repetitive active tDCS stimulation resulted in significant reduction of pain intensity in migraine as compared to sham stimulation. We also observed a trend for reduction in the duration of migraine episode. Based on literature review, we also found migraine days per month and number of migraine attacks could be improved.

Our results suggest that there is a long-term sustained benefit of repetitive tDCS at least 4 weeks. The results from a meta-analysis in 201616 were consistent with our findings in terms of the reduction of pain intensity and number of migraine attacks. However, we did not find a significant decrease for pain medication intake as reported in their meta-analysis. Further evaluation found that the previous analysis misused the duration of each migraine attack as the number of pain medication intake (data extracted from Rocha’s study26), leading to an erroneous conclusion that pain medication use was decreased after tDCS. Additionally, there is a significant mismatch of the pain medication intake at baseline between sham group and the tDCS treatment group in Rocha’s study.26 Future studies with larger sample sizes and matched group assignment are needed for validation.

Stimulation parameters, such as stimulation polarity, electrode montage, duration of each session, number of sessions, and current intensity are selected to achieve the desired therapeutic effect of tDCS.28 At present, the 10/20 electroencephalography (EEG) electrode placement system is usually used to guide the montage for the placement of tDCS anode and cathode electrodes using a variety of stimulation protocols.29 In general, anodal stimulation is presumed to result in depolarization whereas cathodal stimulation results in hyperpolarization.11 However, stimulation of either polarity may have both depolarizing and/or hyperpolarizing effects. For example, anodal and cathodal tDCS applied to Wernicke’s area improved semantic processing compared to sham stimulation in healthy subjects.30 In patients with stroke, anodal stimulation improved manual dexterity and cathodal stimulation seemed to have some benefit for force improvement.31

In our meta-analysis, both anodal and cathodal stimulation were significantly effective in the reducing pain intensity. Importantly, studies with cathodal stimulation targeted the occipital region while studies using anodal stimulation targeted M1 or DLFPC. Our finding is consistent with polarity to be dependent on the targeted region for therapeutic effect. Both occipital cathodal stimulation and anodal primary motor stimulation were selected in the respective studies based on the current understanding of pathophysiology of migraine. With at least two potential regional targets, future studies should be designed to compare montages to determine optimal treatment effects.

Depending on the montage configurations, the electrical field generated via tDCS generally spreads to nearby cortical and subcortical structures.10 Duration of electrical changes is typically maintained only for an hour locally after one time tDCS treatment,11 while sustained and repeated tDCS sessions can provoke cumulative and long-lasting neuroplastic changes in the cerebral cortex.12 Even though the majority of current clinical trials using tDCS for a variety of neurological disorders have been limited by the number of sessions (many studies report findings after 10 or less daily sessions), those that have used extended designs have demonstrated cumulative behavioral13,14 and motor15 effects. Recently, tDCS studies have been performed with an increased diversity of montages. Yet, no standard is available for montage configuration.32 Some researchers have suggested that the efficacy of tDCS in chronic migraine is dependent on individualized montage design guided by thermography, which can be customized to each single patient.33

In terms of study design, assessment of migraine-related disability as one of the outcomes in tDCS clinical trials is necessary to fully evaluate the efficacy of tDCS on migraine. In our review, most of the studies did not consider the impact of tDCS on migraine-related disability. Only in one study, HIT-6 and SF-36 were used. This study did report an improvement in HIT-6 and quality of life after tDCS.27 Pinchuk et al measured the level of state anxiety and trait anxiety, which significantly decreased after tDCS treatment.34 Additionally, the assessment of pain control in migraine patients is a subjective self-evaluation, which may change due to hormonal influence and their own ethnic and cultural differences.35 However, if data collection during baseline and other endpoints is completed for at least four to five weeks (one menstrual cycle), hormonal influence may be minimized. Therefore, baseline period of at least 4 weeks is necessary when evaluating tDCS benefit in migraine. Lastly, it may be helpful to perform subgroup analyses to compare treatment response in men and women separately.

Future clinical trials using tDCS in migraine may include administering tDCS while simultaneously measuring neuronal activity using EEG or fMRI to better understand the underlying mechanism of action. High-definition transcranial direct current stimulation (HD-tDCS), which can provide more focal stimulation in selected brain regions,36,37 is effective in facilitating the rate of verbal learning and working memory in healthy subjects38 and aphasia recovery in patients with stroke.39 However, HD-tDCS does not have the advantage of remote administration at home via telehealth, which can be done using standard tDCS. In addition, the combination of tDCS with other non-pharmacological therapy for migraine may provide synergy and long-term effects.

Our meta-analysis study has some limitations. First, our analyses did not include studies with insufficient data, such as the study of Wickmann et al40 which only reported p-values, but their results supported our conclusion. Second, we rescaled pain intensity in some studies, which led to an estimated assessment. Furthermore, the heterogeneity of these studies and small sample sizes limit our conclusion to a certain extent.